25356-68-7

Basic information

• Product Name: (11alpha,17beta)-11,17-dihydroxy-17-methylandrosta-1,4-dien-3-one
• Synonyms: 11alpha,17beta-Dihydroxy-17alpha-methylandrosta-1,4-dien-3-one
• CAS NO: 25356-68-7
• Molecular Formula: C₂₀H₂₈O₃
• Molecular Weight: 316.4345
• Mol File: 25356-68-7.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 478.4°C at 760 mmHg
• Flash Point: 257.2°C
• Density: 1.19g/cm³
• Vapor Pressure: 3.68E-11mmHg at 25°C
• Refractive Index: 1.59
• CAS DataBase Reference: (11alpha,17beta)-11,17-dihydroxy-17-methylandrosta-1,4-dien-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: (11alpha,17beta)-11,17-dihydroxy-17-methylandrosta-1,4-dien-3-one(25356-68-7)
• EPA Substance Registry System: (11alpha,17beta)-11,17-dihydroxy-17-methylandrosta-1,4-dien-3-one(25356-68-7)

Safety Data

• Hazardous Substances Data: 25356-68-7(Hazardous Substances Data)

Usage

General Description

(11alpha,17beta)-11,17-dihydroxy-17-methylandrosta-1,4-dien-3-one is a chemical compound known as a synthetic anabolic steroid. It is a derivative of testosterone and has both androgenic and anabolic properties. (11alpha,17beta)-11,17-dihydroxy-17-methylandrosta-1,4-dien-3-one is often used in the medical field to treat conditions such as delayed puberty, muscle wasting diseases, and osteoporosis. However, it is also commonly used illicitly by athletes and bodybuilders to enhance muscle growth and performance. The use of this compound outside of medical supervision can lead to serious side effects such as liver damage, cardiovascular issues, and hormonal imbalances. Overall, "(11alpha,17beta)-11,17-dihydroxy-17-methylandrosta-1,4-dien-3-one" has both therapeutic and potentially harmful effects, depending on its usage.

Upstream product

• 72-63-9 metandienone 

Relevant articles and documents

Biotransformation of dianabol with the filamentous fungi and β-glucuronidase inhibitory activity of resulting metabolites

Biotransformation of the anabolic steroid dianabol (1) by suspended-cell cultures of the filamentous fungi Cunninghamella elegans and Macrophomina phaseolina was studied. Incubation of 1 with C. elegans yielded five hydroxylated metabolites 2-6, while M. phaseolina transformed compound 1 into polar metabolites 7-11. These metabolites were identified as 6β,17β-dihydroxy-17α-methylandrost-1,4-dien-3-one (2), 15α,17β-dihydroxy-17α-methylandrost-1,4-dien-3-one (3), 11α,17β-dihydroxy-17α-methylandrost-1,4-dien-3-one (4), 6β,12β,17β-trihydroxy-17α-methylandrost-1,4-dien-3-one (5), 6β,15α,17β-trihydroxy-17α-methylandrost-1,4-dien-3-one (6), 17β-hydroxy-17α-methylandrost-1,4-dien-3,6-dione (7), 7β,17β,-dihydroxy-17α-methylandrost-1,4-dien-3-one (8), 15β,17β-dihydroxy-17α-methylandrost-1,4-dien-3-one (9), 17β-hydroxy-17α-methylandrost-1,4-dien-3,11-dione (10), and 11β,17β-dihydroxy-17α-methylandrost-1,4-dien-3-one (11). Metabolite 3 was also transformed chemically into diketone 12 and oximes 13, and 14. Compounds 6 and 12-14 were identified as new derivatives of dianabol (1). The structures of all transformed products were deduced on the basis of spectral analyses. Compounds 1-14 were evaluated for β-glucuronidase enzyme inhibitory activity. Compounds 7, 13, and 14 showed a strong inhibition of β-glucuronidase enzyme, with IC50 values between 49.0 and 84.9 μM.